DK1156835T3 - Fremgangsmåde til radiomærkning af proteiner med Yttrium-90 - Google Patents

Fremgangsmåde til radiomærkning af proteiner med Yttrium-90

Info

Publication number
DK1156835T3
DK1156835T3 DK00919345T DK00919345T DK1156835T3 DK 1156835 T3 DK1156835 T3 DK 1156835T3 DK 00919345 T DK00919345 T DK 00919345T DK 00919345 T DK00919345 T DK 00919345T DK 1156835 T3 DK1156835 T3 DK 1156835T3
Authority
DK
Denmark
Prior art keywords
yttrium
kits
methods
radiolabeling proteins
radiolabeling
Prior art date
Application number
DK00919345T
Other languages
English (en)
Inventor
Paul Chinn
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK1156835T3 publication Critical patent/DK1156835T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • G01N33/534Production of labelled immunochemicals with radioactive label
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK00919345T 1999-03-01 2000-02-29 Fremgangsmåde til radiomærkning af proteiner med Yttrium-90 DK1156835T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25933899A 1999-03-01 1999-03-01
PCT/US2000/005078 WO2000052031A2 (en) 1999-03-01 2000-02-29 Kit for radiolabeling proteins with yttrium-90

Publications (1)

Publication Number Publication Date
DK1156835T3 true DK1156835T3 (da) 2009-08-03

Family

ID=22984528

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00919345T DK1156835T3 (da) 1999-03-01 2000-02-29 Fremgangsmåde til radiomærkning af proteiner med Yttrium-90

Country Status (36)

Country Link
US (3) US6994840B1 (da)
EP (2) EP2011520A1 (da)
JP (1) JP4558947B2 (da)
KR (1) KR100734023B1 (da)
CN (1) CN1251767C (da)
AT (1) ATE428446T1 (da)
AU (1) AU780311B2 (da)
BG (1) BG65568B1 (da)
BR (1) BR0008635A (da)
CA (1) CA2362908C (da)
CY (1) CY1109211T1 (da)
CZ (1) CZ20013127A3 (da)
DE (2) DE60042014D1 (da)
DK (1) DK1156835T3 (da)
EE (1) EE05582B1 (da)
ES (1) ES2165830T3 (da)
GR (1) GR20010300078T1 (da)
HK (1) HK1045656B (da)
HR (1) HRP20010713A2 (da)
HU (1) HU227986B1 (da)
IL (2) IL145112A0 (da)
ME (1) ME00783B (da)
MX (1) MXPA01008745A (da)
MY (1) MY133346A (da)
NO (1) NO330728B1 (da)
NZ (1) NZ513667A (da)
PL (1) PL204239B1 (da)
PT (1) PT1156835E (da)
RS (1) RS50342B (da)
RU (1) RU2221807C2 (da)
SI (1) SI1156835T1 (da)
SK (1) SK287650B6 (da)
TW (1) TWI283178B (da)
UA (1) UA75036C2 (da)
WO (1) WO2000052031A2 (da)
ZA (1) ZA200106945B (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
AU2001296507A1 (en) 2000-10-02 2002-04-15 Chiron Corporation Human anti-cd40 antibodies
US6696060B2 (en) * 2001-06-14 2004-02-24 Clearant, Inc. Methods for sterilizing preparations of monoclonal immunoglobulins
US7252799B2 (en) 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
US6783968B2 (en) 2001-09-24 2004-08-31 Clearant, Inc. Methods for sterilizing preparations of glycosidases
US6974563B2 (en) 2002-06-18 2005-12-13 Lynntech, Inc. Ion exchange materials for the separation of 90Y from 90SR
EP1596806A4 (en) * 2003-01-27 2007-08-29 Biogen Idec Inc COMPOSITIONS AND METHODS FOR TREATING CANCER USING IGSF9 AND LIV-1
ES2486845T3 (es) * 2003-04-15 2014-08-19 Algeta Asa Torio-227 para ser usado en radioterapia de enfermedad de partes blandas
DE602004028643D1 (de) 2003-11-04 2010-09-23 Novartis Vaccines & Diagnostic Verfahren zur behandlung von soliden tumoren mit expression des cd40-zelloberflächen-antigens
AU2004287480B2 (en) 2003-11-04 2011-09-15 Novartis Vaccines And Diagnostics, Inc. Use of antagonist anti-CD40 antibodies for treatment of chronic lymphocytic leukemia
WO2005044854A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Antagonist anti-cd40 monoclonal antibodies and methods for their use
US20070098718A1 (en) 2003-11-04 2007-05-03 Chiron Methods of therapy for b cell-related cancers
WO2005044855A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
DK1889065T3 (da) 2005-05-18 2013-09-02 Xoma Technology Ltd Metoder til diagnostisering og behandling af sygdomme med en autoimmun- og/eller inflammationskomponent
CN101426817B (zh) 2006-04-21 2013-07-10 诺华有限公司 拮抗性抗-cd40抗体药物组合物
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
ES2548014T3 (es) 2008-07-16 2015-10-13 Institute For Research In Biomedicine Anticuerpos neutralizantes del citomegalovirus humano y uso de los mismos
PE20141432A1 (es) 2008-07-16 2014-10-18 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
MX2011000768A (es) 2008-07-25 2011-10-05 Inst Research In Biomedicine Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.
AU2009305113B2 (en) 2008-10-13 2015-07-16 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
US20110212106A1 (en) 2010-01-20 2011-09-01 Institute For Research In Bioscience Hiv-1 neutralizing antibodies and uses thereof
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
WO2011147762A2 (en) * 2010-05-25 2011-12-01 Bayer Pharma Aktiengesellschaft Stabilized radiopharmaceutical composition
KR20140045312A (ko) * 2010-12-22 2014-04-16 제너럴 일렉트릭 캄파니 방사성표지 her2 결합 펩티드
HUE044089T2 (hu) 2011-07-18 2019-09-30 Inst Res Biomedicine Neutralizáló anti-influenza A antitestek és alkalmazásaik
NZ630920A (en) 2012-03-20 2017-01-27 Humabs Biomed Sa Antibodies that neutralize rsv, mpv and pvm and uses thereof
RU2537175C2 (ru) * 2013-03-26 2014-12-27 Российская Федерация, От Имени Которой Выступает Министерство Образования И Науки Российской Федерации Способ получения радиоиммунного препарата для диагностики и терапии онкологических заболеваний
EA033403B1 (ru) 2013-08-13 2019-10-31 Sanofi Sa Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
ES2837392T3 (es) 2013-10-02 2021-06-30 Medimmune Llc Anticuerpos anti-influenza A neutralizantes y usos de los mismos
CA2954780A1 (en) 2014-07-15 2016-01-21 Medimmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
US20170296650A1 (en) 2014-10-08 2017-10-19 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
WO2016075546A2 (en) 2014-11-14 2016-05-19 Antonio Lanzavecchia Antibodies that neutralize ebola virus and uses thereof
DK3220947T3 (da) 2014-11-18 2020-11-30 Humabs Biomed S A Antistoffer som potent neutraliserer rabiesvirus og øvrige lyssavirusser og anvendelser deraf
IL237525A (en) * 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
GB201504064D0 (en) 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
AU2016271323B2 (en) 2015-06-01 2022-08-25 Medimmune, Llc Neutralizing anti-influenza binding molecules and uses thereof
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
CN116271017A (zh) 2016-01-13 2023-06-23 免疫医疗有限责任公司 治疗甲型流感的方法
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
CN110945022B (zh) 2017-04-19 2024-04-05 生物医学研究所 作为疫苗及新疟疾疫苗和抗体结合靶标的疟原虫子孢子npdp肽
AU2018265888A1 (en) * 2017-05-12 2019-11-21 Memorial Sloan-Kettering Cancer Center Use of anti-B7H3 antibodies for treating cancer in the central nervous system
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
SI3898668T1 (sl) 2018-12-19 2024-02-29 Humabs Biomed Sa Protitelesa, ki nevtralizirajo virus hepatitisa B in njihove uporabe
US20220380441A1 (en) 2019-08-29 2022-12-01 Vir Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
CN111116701A (zh) * 2019-11-14 2020-05-08 浙江普罗亭健康科技有限公司 一种用于蛋白金属标记的中间体及其制备方法、用途
TW202208422A (zh) 2020-06-24 2022-03-01 美商維爾生物科技股份有限公司 經工程化之b型肝炎病毒中和抗體及其用途
JP2024504167A (ja) 2021-01-26 2024-01-30 ヴィア・バイオテクノロジー・インコーポレイテッド B型肝炎ウイルス感染を処置するための抗体組成物および方法
WO2024068944A1 (en) 2022-09-30 2024-04-04 Sanofi Anti-cd28 antibodies
WO2024089609A1 (en) 2022-10-25 2024-05-02 Ablynx N.V. Glycoengineered fc variant polypeptides with enhanced effector function
US20240209107A1 (en) 2022-12-19 2024-06-27 Sanofi Cd28/ox40 bispecific antibodies

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994966A (en) 1972-09-28 1976-11-30 The Board Of Trustees Of The Leland Stanford Junior University Chelating agents
US4043998A (en) 1974-10-09 1977-08-23 The Board Of Trustees Of The Leland Stanford Junior University 1-(P-benzenediazonium)-ethylenediamine tetraacetic acid
US4315851A (en) 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4460561A (en) 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4460559A (en) 1980-03-03 1984-07-17 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4622420A (en) 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
US4454106A (en) 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4707352A (en) 1984-01-30 1987-11-17 Enzo Biochem, Inc. Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
US4636380A (en) 1984-04-23 1987-01-13 Wong Dennis W Novel physiologic chemical method of labeling protein substances with the radionuclides of indium
US4634586A (en) 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
US4722892A (en) 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
US4824986A (en) 1985-04-26 1989-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metal chelate protein conjugate
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4926869A (en) 1986-01-16 1990-05-22 The General Hospital Corporation Method for the diagnosis and treatment of inflammation
AU593611B2 (en) 1986-02-14 1990-02-15 Nihon Medi-Physics Co., Ltd. High molecular compounds having amino groups, and their utilization
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
EP0529645B1 (en) * 1986-09-05 1996-10-23 GANSOW, Otto A. Process for the preparation of backbone polysubstituted chelates
US5034223A (en) 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4921690A (en) 1986-12-29 1990-05-01 City Of Hope Method of enhancing the biodistribution of antibody for localization in lesions
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU619218B2 (en) 1987-11-06 1992-01-23 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5217704A (en) 1987-11-06 1993-06-08 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5130118A (en) 1987-11-06 1992-07-14 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US4923985A (en) 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
ATE134999T1 (de) 1988-05-25 1996-03-15 Us Commerce Makrocyclische chelate und verwendungsverfahren
US5059518A (en) 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
CA2010511A1 (en) 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
US5376356A (en) 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation
US5162115A (en) 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5219556A (en) 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes
US5009069A (en) 1990-08-24 1991-04-23 Molini Alberto E Method of recovering energy from ocean water
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
JPH06501705A (ja) 1990-11-05 1994-02-24 ブリストル−マイアーズ スクイブ カンパニー 抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療
US5208008A (en) 1990-11-14 1993-05-04 University Of Pittsburgh Regioselective chemical modification of monoclonal antibodies
CA2075928A1 (en) 1991-01-11 1992-07-12 Roger W. Hackett Method of detecting circulating antibody types using dried or lyophilized cells or cell-like material
US5403573A (en) 1992-04-23 1995-04-04 The Curators Of The University Of Missouri Radiolabeled protein composition and method for radiation synovectomy
US5541287A (en) 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5650134A (en) * 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DE69534495D1 (de) * 1994-01-24 2006-02-16 Sumitomo Chemical Co Laminat, laminierter film und formartikel
IL113610A0 (en) 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5728369A (en) 1994-10-05 1998-03-17 Immunomedics, Inc. Radioactive phosphorus labeling of proteins for targeted radiotherapy
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5942210A (en) * 1994-11-15 1999-08-24 Cytogen Corporation Methods for lyoprotecting a macromolecule using tricine
US5830431A (en) 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US6300143B1 (en) 1999-03-01 2001-10-09 Idec Pharmaceuticals Corporation Electrochemiluminescent assays for eukaryotic cells
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90

Also Published As

Publication number Publication date
HK1045656B (zh) 2006-09-22
PL350551A1 (en) 2002-12-16
HUP0105489A2 (hu) 2002-05-29
SK287650B6 (sk) 2011-05-06
EP1156835A2 (en) 2001-11-28
NO20014239L (no) 2001-11-01
SK12172001A3 (sk) 2002-05-09
NO20014239D0 (no) 2001-08-31
AU780311B2 (en) 2005-03-17
ME00783B (me) 2012-03-20
DE1156835T1 (de) 2002-05-23
WO2000052031A2 (en) 2000-09-08
MXPA01008745A (es) 2002-04-24
EP2011520A1 (en) 2009-01-07
BG65568B1 (bg) 2008-12-30
US7229620B2 (en) 2007-06-12
BR0008635A (pt) 2001-12-26
KR20020002474A (ko) 2002-01-09
US20060067884A1 (en) 2006-03-30
HUP0105489A3 (en) 2005-10-28
MY133346A (en) 2007-11-30
CN1345249A (zh) 2002-04-17
RS50342B (sr) 2009-11-10
CA2362908A1 (en) 2000-09-08
HRP20010713A2 (en) 2002-12-31
KR100734023B1 (ko) 2007-06-29
DE60042014D1 (de) 2009-05-28
ES2165830T1 (es) 2002-04-01
PT1156835E (pt) 2009-07-24
HU227986B1 (en) 2012-07-30
HK1045656A1 (en) 2002-12-06
AU4004600A (en) 2000-09-21
IL145112A (en) 2007-05-15
EP1156835B1 (en) 2009-04-15
US20070297978A1 (en) 2007-12-27
CY1109211T1 (el) 2014-07-02
TWI283178B (en) 2007-07-01
SI1156835T1 (sl) 2009-08-31
ZA200106945B (en) 2002-11-22
WO2000052031A3 (en) 2001-03-01
CN1251767C (zh) 2006-04-19
CZ20013127A3 (cs) 2002-02-13
NZ513667A (en) 2001-09-28
EE200100461A (et) 2002-10-15
GR20010300078T1 (en) 2002-01-31
ES2165830T3 (es) 2009-06-19
YU61701A (sh) 2004-05-12
PL204239B1 (pl) 2009-12-31
US7618613B2 (en) 2009-11-17
JP4558947B2 (ja) 2010-10-06
BG105853A (en) 2002-06-28
JP2002538164A (ja) 2002-11-12
IL145112A0 (en) 2002-06-30
US6994840B1 (en) 2006-02-07
NO330728B1 (no) 2011-06-27
CA2362908C (en) 2012-01-31
RU2221807C2 (ru) 2004-01-20
UA75036C2 (uk) 2006-03-15
EE05582B1 (et) 2012-10-15
ATE428446T1 (de) 2009-05-15

Similar Documents

Publication Publication Date Title
DK1156835T3 (da) Fremgangsmåde til radiomærkning af proteiner med Yttrium-90
JP2769244B2 (ja) 蛋白質のテクネチウム/レニウム標識方法
DK0927192T3 (da) Modificerede aminosyrer, lægemidler indeholdende disse forbindelser og fremgangsmåder til deres fremstilling
EA200001169A1 (ru) Специфично связывающиеся молекулы для сцинтиграфии, содержащие их конъюгаты и терапевтический способ лечения ангиогенеза
DK1345895T3 (da) Hidtil ukendt diphenylazetidioner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse til behandling af lipidstofskifteforstyrrelser
DE69417426D1 (de) N2s2-chelatoren des hydrazino-typs
DK0699687T3 (da) Fremgangsmåde til oprensning af rekombinant humant serumalbumin
DE69321555D1 (de) ECK-Rezeptor-Liganden
DE69434384D1 (de) Metalkomplexbildner
WO2002046222A3 (en) Compositions and methods for diagnosing alzheimer's disease
ZA200007211B (en) Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis.
DK304090A (da) Glycerolderivater, fremgangsmaade til deres fremstilling og terapeutiske praeparater indeholdende disse
DK1062244T3 (da) Forbedrede fremgangsmåder til fremstilling af faktor VIII proteiner
IS4957A (is) Hreinsuð prótein, samskeyttar DNA raðir og aðferðir til að stýra þroskun kaffiplantna
EP1539221A4 (en) TRANSFERRIN Fusion Protein LIBRARIES
BR0211130A (pt) Plantas transgênicas que expressam proteìnas de ligação da cobalamina
NO20024325D0 (no) Rensede hepatitt C-viruskappeproteiner for diagnostisk og terapeutisk anvendelse
DK62690A (da) Sdk-peptider, fremgangsmaade til deres fremstilling og terapeutisk praeparat indeholdende disse
DK1156330T3 (da) Fremgangsmåde til isotopmærkning af protein med enzym
de la Torre et al. Hydroxyapatite-based 99Mo/99mTc and 188W/188Re generator systems
DK276690A (da) Selenophenderivater, fremgangsmaade til deres fremstilling og terapeutiske praeparater indeholdende disse
DK381787D0 (da) Rensede antigener med vaccineegenskaber mod b. pertussis, midler, navnlig rekombinant-dna, til fremstilling deraf og vaccinepraeparater indeholdende disse